1 / 1

LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035

According to DelveInsight, the LAG-3-Next Generation Immunotherapy market is expected to generate USD 3,421 Million in the year 2035 with a significant CAGR in the forecast period. NSCLC will occupy the major market share that is 98.81% by 2035. <br><br>Launch of potential upcoming therapies, the addition of personalised drug therapies with combination therapies for efficacy enhancement, increased funding for R&D expense, understanding of disease and pathogenesis are some of the key factors expected to drive the LAG-3-Next Generation Immunotherapy market in upcoming years.<br><br>The key players in LAG-3-Next Generation Immunotherapy market include MacroGenics, Zai Lab, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, Regeneron, Xencor, Incyte Biosciences, Agenus, Roche, GlaxoSmithKline, Innovent Biologics (Suzhou) Co. Ltd. and others.<br><br><br>For more information visit: https://www.delveinsight.com/report-store/LAG-3-next-generation-immunotherapy-competitive-landscape<br>

DelveInsight
Télécharger la présentation

LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related